Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine Among Actively Treated Cancer Patients

BACKGROUND: Activity and safety of the SARS-CoV-2 BNT162b2 vaccine in actively treated patients with solid tumors is currently unknown. METHODS: We conducted a retrospective study of 326 patients with solid tumors treated with anticancer medications to determine the proportion of cancer patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Ligumsky, Hagai, Safadi, Esraa, Etan, Tal, Vaknin, Noam, Waller, Manuel, Croll, Assaf, Nikolaevski-Berlin, Alla, Greenberg, Inbal, Halperin, Tami, Wasserman, Asaf, Galazan, Lior, Arber, Nadir, Wolf, Ido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499747/
https://www.ncbi.nlm.nih.gov/pubmed/34453830
http://dx.doi.org/10.1093/jnci/djab174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499747/
https://www.ncbi.nlm.nih.gov/pubmed/34453830
http://dx.doi.org/10.1093/jnci/djab174

Ejemplares similares